Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...
Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...
GlobalData on MSN2d
Globus Medical strengthens SCS market position with $250m Nevro dealGlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Hosted on MSN4d
Piper Sandler Upgrades Nevro (NVRO)Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...
The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback